1. Harvey, J.M., Clark, G.M., Osborne, C.K. & Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17, 1474-1481 (1999).
2. Abe, O. et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. Chlebowski, R.T., Schottinger, J.E., Shi, J.X., Chung, J. & Haque, R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 121, 2147-2155 (2015).
4. Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
5. Wei, C.W. et al. Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 111, E601-E610 (2014).
6. Wang, Q. et al. Tamoxifen enhances stemness and promotes metastasis of ER alpha 36(+) breast cancer by upregulating ALDH1A1 in cancer cells. Cell Research 28, 336-358 (2018).
7. Brzozowski, A.M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997).
8. Wang, Z.Y. et al. A variant of estrogen receptor-alpha, hER-alpha 36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proceedings of the National Academy of Sciences of the United States of America 103, 9063-9068 (2006).
9. Shen, Y.Y. et al. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha 36. Oncology Reports 39, 2604-2612 (2018).
10. Shou, J. et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor- HER2/neu cross-talk in ER/HER2-positive breast cancer. Jnci-Journal of the National Cancer Institute 96, 926-935 (2004).
11. Acconcia, F., Barnes, C.J. & Kumar, R. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147, 1203-1212 (2006).
12. Gottardis, M.M., Robinson, S.P., Satyaswaroop, P.G. & Jordan, V.C. CONTRASTING ACTIONS OF TAMOXIFEN ON ENDOMETRIAL AND BREAST-TUMOR GROWTH IN THE ATHYMIC MOUSE. Cancer Research 48, 812-815 (1988).
13. Gottardis, M.M. & Jordan, V.C. DEVELOPMENT OF TAMOXIFEN- STIMULATED GROWTH OF MCF-7 TUMORS IN ATHYMIC MICE AFTER LONG-TERM ANTIESTROGEN ADMINISTRATION. Cancer Research 48, 5183-5187 (1988).
14. Pasquale, E.B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52 (2008).
15. Wykosky, J. & Debinski, W. The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting. Molecular Cancer Research 6, 1795-1806 (2008).
16. Yeddula, N., Xia, Y.F., Ke, E., Beumer, J. & Verma, I.M. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 112, E6476-E6485 (2015).
17. Wiedemann, E. et al. Regulation of endothelial migration and proliferation by ephrin-A1. Cellular Signalling 29, 84-95 (2017).
18. Hamaoka, Y., Negishi, M. & Katoh, H. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cellular Signalling 28, 937-945 (2016).
19. Barquilla, A. et al. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Molecular Biology of the Cell 27, 2757-2770 (2016).
20. Zhou, Y. et al. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nature Communications 6 (2015).
21. Yonehara, K. et al. RSK-mediated non-canonical activation of EphA2 by tamoxifen. Biological and Pharmaceutical Bulletin (now revising).
22. Yamada,K. et al. Different PDGF Receptor Dimers Drive Distinct Migration Modes of the Mouse Skin Fibroblast. Cellular Physiology and Biochemistry 51 (2018).
23. McDonnell, D.P. & Wardell, S.E. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Current Opinion in Pharmacology 10, 620-628 (2010).
24. Puranik, N.V. et al. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ER alpha) by various parameters and molecular modelling approach. Scientific Reports 9 (2019).
25. Pike, A.C.W., Brzozowski, A.M. & Hubbard, R.E. A structural biologist's view of the oestrogen receptor. Journal of Steroid Biochemistry and Molecular Biology 74, 261-268 (2000).
26. McDonnell, D.P., Wardell, S.E. & Norris, J.D. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. Journal of Medicinal Chemistry 58, 4883-4887 (2015).
27. Friedl, A. & Jordan, V.C. ESTRADIOL STIMULATES GROWTH OF ESTROGEN RECEPTOR-NEGATIVE MDA-MB-231 BREAST-CANCER CELLS IN IMMUNODEFICIENT MICE BY REDUCING CELL LOSS. European Journal of Cancer 30A, 1559-1564 (1994).
28. Gu, W.W. et al. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-alpha 36 signaling in vitro. Cell Biology and Toxicology 33, 183-195 (2017).
29. Hiramoto-Yamaki, N. et al. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. Journal of Cell Biology 190, 461-477 (2010).
30. Zhuang, G.L., Hunter, S., Hwang, Y. & Chen, J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation. Journal of Biological Chemistry 282, 2683-2694 (2007).
31. Gundry, C. et al. Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell: cell repulsion. Nature Communications 8 (2017).
32. Zhang, J.Q. et al. RCP is a human breast cancer-promoting gene with Ras- activating function. Journal of Clinical Investigation 119, 2171-2183 (2009).
33. Sugiyama, N. et al. EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. Journal of Cell Biology 201, 467-484 (2013).
34. Krueger, J.S., Keshamouni, V.G., Atanaskova, N. & Reddy, K.B. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20, 4209-4218 (2001).
35. Schrecengost, R.S., Riggins, R.B., Thomas, K.S., Guerrero, N.S. & Bouton, A.H. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130(Cas) membrane localization and membrane ruffling. Cancer Research 67, 6174-6182 (2007).
36. Higuchi, T. et al. Variation in Use of Estrogen Receptor-alpha Gene Promoters in Breast Cancer Compared by Quantification of Promoter-Specific Messenger RNA. Clinical Breast Cancer 14, 249-257 (2014).
37. Hirata, S., Shoda, T., Kato, J. & Hoshi, K. Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends in Endocrinology and Metabolism 14, 124- 129 (2003).
38. Springwald, A. et al. Identification of novel transcript variants of estrogen receptor alpha, beta and progesterone receptor gene in human endometrium. Endocrine 37, 415-424 (2010).
39. Poola, I., Koduri, S., Chatra, S. & Clarke, R. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. Journal of Steroid Biochemistry and Molecular Biology 72, 249-258 (2000).
40. Hattori, Y. et al. Human C-terminally truncated ER alpha variants resulting from the use of alternative exons in the ligand-binding domain. Molecular and Cellular Endocrinology 425, 111-122 (2016).
41. Li, L., Haynes, M.P. & Bender, J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 100, 4807-4812 (2003).
42. Wang, Z.Y. et al. Identification, cloning, and expression of human estrogen receptor-alpha 36, a novel variant of human estrogen receptor-alpha 66. Biochemical and Biophysical Research Communications 336, 1023-1027 (2005).
43. Schreihofer, D.A., Duong, P. & Cunningham, R.L. N-terminal truncations in sex steroid receptors and rapid steroid actions. Steroids 133, 15-20 (2018).
論文の公開元へ
